ArticleBioorganic & medicinal chemistry2009
Inhibition of S-ribosylhomocysteinase (LuxS) by substrate analogues modified at the ribosyl C-3 position.
Article in Bioorganic & medicinal chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Phytochemical Quorum-Sensing Inhibitors Against Bacterial Pathogens: Mechanisms of Action and Translational Challenges.Current issues in molecular biology · 2026Review
- Next-generation anti-infective drugs in the post-antibiotic era: focusing on anti-virulence agents targeting the bacterial quorum sensing system.Frontiers in cellular and infection microbiology · 2026Review
- Bringing Antimicrobial Strategies to a New Level: The Quorum Sensing System as a Target to ControlLife (Basel, Switzerland) · 2022Review
- Exploring interfacial dynamics in homodimericRSC advances · 2021Article
- Regulatory Mechanisms of the LuxS/AI-2 System and Bacterial Resistance.Antimicrobial agents and chemotherapy · 2019Review
- Designer cells programming quorum-sensing interference with microbes.Nature communications · 2018Article
- The LuxS/AI-2 Quorum-Sensing System ofFrontiers in cellular and infection microbiology · 2018Article
- Interference With Quorum-Sensing Signal Biosynthesis as a Promising Therapeutic Strategy Against Multidrug-Resistant Pathogens.Frontiers in cellular and infection microbiology · 2018Review
- Reduction of sugar lactones to hemiacetals with lithium triethylborohydride.Carbohydrate research · 2016Article
- S-Ribosylhomocysteine analogs containing a [4-thio]ribose ring.Carbohydrate research · 2015Article
- Screening of Actinobacillus pleuropneumoniae LuxS inhibitors.Current microbiology · 2013Article
- Small molecule inhibitors of AI-2 signaling in bacteria: state-of-the-art and future perspectives for anti-quorum sensing agents.International journal of molecular sciences · 2013Article
- Exploiting quorum sensing to confuse bacterial pathogens.Microbiology and molecular biology reviews : MMBR · 2013Review
- Crystallization and preliminary X-ray analysis of S-ribosylhomocysteinase from Streptococcus mutans.Acta crystallographica. Section F, Structural biology and crystallization communications · 2012Article
- Substituted lactam and cyclic azahemiacetals modulate Pseudomonas aeruginosa quorum sensing.Bioorganic & medicinal chemistry · 2011Article
- Inhibition of LuxS by S-ribosylhomocysteine analogues containing a [4-aza]ribose ring.Bioorganic & medicinal chemistry · 2011Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
S-ribosylhomocysteinase (LuxS) catalyzes the cleavage of the thioether bond of S-ribosylhomocysteine (SRH) to produce homocysteine and 4,5-dihydroxy-2,3-pentanedione (DPD), which is the precursor of type 2 autoinducer for bacterial cell-cell communication. In this work, we have synthesized several SRH analogues modified at the ribose C3 position as potential inhibitors of LuxS. While removal or methylation of the C3-OH resulted in simple competitive inhibitors of moderate potency, inversion of the C3 stereochemistry or substitution of fluorine for C3-OH resulted in slow-binding inhibitors of improved potency. The most potent inhibitor showed a K(I)(*) value of 0.43 microM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.